Antisense oligonucleotides as an innovative therapeutic strategy in the treatment of high-grade gliomas

Recent Patents on CNS Drug Discovery

Volumn 5, Issue 1, 2010, Pages 53-69

  Caruso, Gerardo ^a   Caffo, Mariella ^a   Raudino, Giuseppe ^a   Alafaci, Concetta ^a   Salpietro, Francesco M ^a   Tomasello, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Angiogenesis; Antisense oligonucleotides; Extracellular matrix proteins; High grade gliomas; Nanoparticles

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARBON NANOTUBE; CGP 69846A; FIBRONECTIN; HYALURONIC ACID; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE; NANOPARTICLE; NANOSHELL; PRODRUG; QUANTUM DOT; TENASCIN; VITRONECTIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; SCLEROPROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CELL DIFFERENTIATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; HYBRIDIZATION; MICROGLIA; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; GENETICS; NERVOUS SYSTEM TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; EXTRACELLULAR MATRIX PROTEINS; GLIOMA; HUMANS; NERVOUS SYSTEM NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 77449153837     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488910789753503     Document Type: Review

References (152)

1. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61(3): 215-229.
2. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: Genetics and biology of a grave matter. Genes Dev 2001; 15(11): 1311-1333.
3. Burger PC, Dubois PJ, Schold SC, et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983; 58(2): 159-169.
4. Gaspar LE, Fisher BJ, MacDonald DR, et al. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992; 24(1): 55-57.
5. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6(7): 2585-2597.
6. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4(9): 1364-1368.
7. Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 2005; 353(19): 1997-1999.
8. Meng Y, Carpentier AF, Chen L, et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 2005; 116(6): 992-997.
9. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms: An update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11(2): 165-180.
10. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12(16): 4899-4907.
11. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel((R)) wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006; 148(3): 269-275.
12. Fenstermaker RA, Ciesielski MJ. Immunotherapeutic strategies for malignant glioma. Cancer Control 2004; 11(3): 181-191.
13. Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 2005; 103(1): 156-164.
14. Gonzalez J, Gilbert MR. Treatment of astrocytomas. Curr Opin Neurol 2005; 18(6): 632-638.
15. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: Current clinical status. Mol Ther 2005; 12(4): 585-598.
16. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-996.
17. Sanson M, Laigle-Donadey F, Benouaich-Amiel A. Molecular changes in brain tumors: Prognostic and therapeutic impact. Curr Opin Oncol 2006; 18(6): 623-630.
18. Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006; 65(2): 499-508.
19. Chintala SK, Gokaslan ZL, Go Y, Sawaya R, Nicolson GL, Rao JS. Role of extracellular matrix proteins in regulation of human glioma cell invasion in vitro. Clin Exp Metastasis 1996; 14(4): 358-366.
20. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996; 39(2): 235-252.
21. Tysnes BB, Larsen LF, Ness GO, et al. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Int J Cancer 1996; 67(6): 777-784.
22. Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 1999; 80(5): 764-772.
23. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolamide plus the matrx metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002; 20(5): 1383-1388.
24. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20(14): 1389-1397.
25. Solly SK, Trajcevski S, Frisen C, et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 2003; 10: 30-39.
26. Zhang J, Frolov I, Russell SJ. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J Gene Med 2004; 6(10): 1082-1091.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
28. Holland EC. Gliomagenesis: Genetic alterations and mouse models. Nat Rev Genet 2001; 2(2): 120-129.
29. Stegh AH, Kim H, Bachoo RM, et al. BcI2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007; 21: 98-111.
30. Ohgaki K, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170(5): 1445-1453.
31. Burger PC. Pathologic anatomy and CT correlations in the glioblastoma multiforme. Appl Neurophysiol 1983; 46(1-4): 180-187.
32. Kohn EC, Liotta LA. Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 1995; 55(9): 1856-1862.
33. Chintala SK, Sawaya R, Gokaslan ZL, Fuller G, Rao JS. Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett 1996; 101(1): 107-114.
34. Perris R. The extracellular matrix in neural crest-cell migration. Trends Neurosci 1997; 20(1): 23-30.
35. Paulus W. Brain extracellular matrix, adhesion molecules, and glioma invasion. In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenblum ML, Ed. Brain Tumor Invasion: Biological, Clinical and Therapeutic Considerations. New York: Wiley-Liss 1998.
36. Pinkstaff K, Detterich J, Lynch G, Gall C. Integrin subunit gene expression is regionally differentiated in adult brain. J Neurosci 1999; 19(5): 1541-1556.
37. Jones LS. Integrins: Possible functions in the adult CNS. Trends Neurosci 1996; 19(2): 68-72.
38. Rooprai HK, Vanmeter T, Panou C, et al. The role of integrin receptors in aspects of glioma invasion in vitro. Int J Dev Neurosci 1999; 17(5-6): 613-623.
39. Gladson CL, Wilcox JN, Sanders L, Gillespie GY, Cheresh DH. Cerebral microenviroment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci 1995; 108(Pt 3): 947-956.
40. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001; 49(2): 380-389.
41. Gladson CL. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 1996; 55(11): 1143-1149.
42. Woessner JF. The family of matrix metalloproteinases. Ann NY Acad Sci 1994; 732: 11-21.
43. Uhm JH, Dooley NP, Villemure J-G, Yong VW. Mechanisms of glioma invasion: Role of matrix metalloproteinases. Can J Neurol Sci 1997; 24(1): 3-15.
44. Bello L, Giussani C, Costa F, et al. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004; 117: 263-284.
45. Caffo M, Germanò A, Caruso G, et al. An immunohistochemical study of extracellular matrix proteins laminin, fibronectin and type IV collagen in paediatric glioblastoma multiforme. Acta Neurochir (Wien) 2004; 146(10): 1113-1118.
46. Liekens S, De Clercq E, Neyts J. Angiogenesis: Regulators and clinical application. Biochem Pharmacol 2001; 61(3): 253-270.
47. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353-364.
48. Grau SJ, Trillsch F, Herms J, et al. Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol 2007; 82(2): 141-150.
49. Witmer AN, van Blijswijk BC, Dai J, et al. VEGFR-3 in adult angiogenesis. J Pathol 2001; 195(4): 490-497.
50. Morrison RS, Yamaguchi F, Saya H, et al. Basic fibroblast growth facto rand fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J Neurooncol 1994; 18: 207-216. (Pubitemid 24209422)
51. Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J cancer 2006; 118(9): 2182-2189.
52. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. Trends Neurosci 1996; 19(8): 312-318.
53. Dickson DW, Mattiace LA, Kure K, Hutchins K. Microglia in human disease, with an emphasis on acquired immune deficiency syndrome. Lab Invest 1991; 64(2): 134-156.
54. Smits HA, van Beelen AJ, de Vos NM, et al. Activation of human macrophages by amyloid-beta is attenuated by astrocytes. J Immunol 2001; 166(11): 6869-6876.
55. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophages polarization: Tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23(11): 549-555.
56. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev Cancer 2004; 4: 71-78.
57. Tran CT, Wolz P, Egensperger R, et al. Differential expression of MHC class II molecules by microglia and neoplastic astroglia: Relevance for the escape of astrocytoma cells from immune surveillance. Neuropathol Appl Neurobiol 1998; 24(2): 293-301.
58. Nishie A, Ono M, Shono T, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999; 5(5): 1107-1113.
59. Tsuij A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev 1999; 36(2-3): 277-290. (Pubitemid 29121976)
60. Pardridge WM. Why is the global CNS pharmaceutical market so underpenetrated? Drug Discov Today 2002; 7(1): 5-7.
61. Golden PL, Pollack GM. Blood brain barrier efflux transport. J Pharm Sci 2003; 92(9): 1739-1753.
62. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: A review. J Pharm Pharm Sci 2003; 6(2): 252-273.
63. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Mol Canc Ther 2006; 5(8): 1909-1917.
64. Praetorius NP, Mandal TK. Engineerd nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul 2007; 1(1): 37-51.
65. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomed 2008; 3(2): 133-149.
66. Kim JS, Kuk E, Yu KN, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007; 3: 95-101.
67. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL. Immunoshells for targeted phototermical ablation in medulloblastoma and glioma: An in vitro evaluation using human cell lines. J Neurooncol 2008; 86: 165-172.
68. Kam NW, O'Connell M, Wisdom JA, Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci USA 2005; 102: 11600-11605.
69. Wang CH, Huang YJ, Peng CA. Phototermal ablation of stem-cell like glioblastoma using carbon nanotubes functionalized with anti-CD133. Proceedings 2009; 23: 888-891.
70. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999; 4(3): 209-224.
71. Izquierdo M, Martin V, de Felipe P, et al. Human malignant brain tumor response to Herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 1996; 3(6): 491-495.
72. Ram Z, Culver KW, Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector producing cells. Nat Med 1997; 3(12): 1354-1361.
73. Zhang Z, Yang S, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006; 12(16): 4933-4939.
74. Najlah M, D'Emanuele A. Crossing cellular barriers using dendrimer nanotechnologies. Curr Opin Pharm 2006; 6: 522-527.
75. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR Jr. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules 2006; 7: 572-579.
76. Kukowska-Latallo JF, Candido KA, Cao Z, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005; 65(12): 5317-5324.
77. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007; 28(8): 1565-1571.
78. Mills JK, Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol 2004; 387: 82-113.
79. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1997-11201
80. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer - the tome of truth. Lancet Oncol 2002; 3(11): 672-683.
81. Tamm I. Antisense therapy in malignant disease: status quo and quo vadis? Clin Sci 2006; 110(4): 427-442.
82. Wacheck V, Zangemeister-Wittke U. Anisense molecules for targeted cancer therapy. Oncol Hematol 2006; 59(1): 65-73.
83. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977; 74(10): 4370-4374.
84. Stephenson ML, Zamecnick PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75(1): 285-288.
85. Whitesell L, Rosolen A, Neckers LM. in vivo Modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. Antisense Res Dev 1991; 1(4): 343-350.
86. Baker BF, Condon TP, Koller E, et al. Discovery and analysis of antisense oligonucleotide activity in cell culture. Methods 2001; 23(2): 191-198.
87. Baker BF, Monia BP. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta 1999; 1489(1): 3-18.
88. Dias N, Stein CA. Antisense oligonucleotides: Basic concept and mechanisms. Mol Cancer Ther 2002; 1(5): 347-355.
89. Dean NM, Bennett FC. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003; 22(56): 9087-9096.
90. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 2000; 165(1): 539-547.
91. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000; 6(6): 2469-2473.
92. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. Implication of macrophages in tumor rejection induced by CpGoligodeoxynucleotides without antigen. Clin Cancer Res 2001; 7(11): 3540-3543.
93. Ackermann EJ, Taylor JK, Narayana R, Bennett FC. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J Biol Chem 1999; 274: 11245-11253.
94. Cotter FE. Antisense therapy of hematologic malignancies. Semin Hematol 1999; 36(4 Supp 6): 9-14.
95. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin's lymphoma. J Clin Oncol 1999; 18(9): 1812-1823.
96. Levin AA. A review of issue in the pharmacokinetics and toxicology of phosphorothioate antisense olionucleotides. Biochim Biophys Acta 1999; 1489: 69-84.
97. Kandimalla ER, Manning A, Zhao Q, et al. Mixed backbone antisense oligonucleotides: Design, biochemical and biological properties of oligonucleotides containing 2′-5′-ribo- and 3′-5′- deoxyribonucleotide segments. Nucleic Acid Res 1997; 25(2): 370-378.
98. Summerton J. Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta 1999; 1489(1): 141-158.
99. Nielsen PE. Antisense properties of peptide nucleic acid. Methods Enzymol 2003; 313: 156-164.
100. Orum H, Wengel J. Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development. Curr Opin Mol Ther 2001; 3: 329-343.
101. Bergan L, Connell Y, Fahmy B, Neeckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acid Res 1993; 21(15): 3567-3573.
102. Bonham MA, Brown S, Boyd AL, et al. An assessment of the antisense properties of RNase H-component and steric-blocking oligomers. Nucleic Acid Res 1995; 23(7): 1197-1203.
103. Pardridge M, Vincent A, Matthews P. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev 1996; 6(3): 169-175.
104. Pooga M, Soomets U, Hallbrink M, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16(9): 857-861.
105. Astriab-Fisher A, Sergueev DS, Fisher M, Ramsay Shaw B, Juliano RL. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol 2000; 60(1): 83-90.
106. Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 2003; 41(Suppl 1): 81-88.
107. Jachimczak P, Bogdahn U, Behl C, et al. The effect of transforming growth factor-beta 2-specific phosphorothioateantisense oligodeoxynucleotide in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993; 78: 944-951.
108. Jachimczak P, Hessdorfer B, Fabel-Schulte K, et al. Transforming growth factor-beta mediated autocrine growth regulation of gliomas with phosphorothioate antisense oligonucleotides. Int J Cancer 1996; 65(3): 332-337.
109. Schlingensiepen R, Goldbrunner M, Szyrach MNI, et al. Intracerebral and intrathecal infusion of the TGF-β2-specific antisense phosphorotioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety. Oligonucleotides 2005; 15: 94-104.
110. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006; 17: 129-139.
111. Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies. Oligonucleotides 2007; 17(2): 201-212.
112. Schneider T, Becker A, Ringe K, et al. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 2008; 195(1-2): 21-27.
113. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16(25): 3323-3330.
114. Kondo S, Tanaka Y, Kondo Y, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 1998; 12(10): 801-811.
115. Komata T, Kondo Y, Koga S, Lo SC, Chung LWK, Kondo S. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Ther 2000; 7(24): 2071-2079.
116. Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 2000; 60(16): 4461-4467.
117. Iwado E, Daido S, Kondo Y, Kondo S. Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. Int J Oncol 2007; 31(5): 1087-1095.
118. Grossman SA, Alavi JB, Supko JG, et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-α delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. NeuroOncol 2004; 6: 32-40.
119. McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem 1999; 3: 1715-1722.
120. Potapova O, Gorospe M, Dougherty RH, et al. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 2000; 20(5): 1713-1722.
121. Monia BP, Sasmor H, Johnston J, et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 1996; 93(26): 15481-15484.
122. Chen G, Oh S, Monia BP, Stacey DW. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996; 271(45): 28259-28265.
123. Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999; 59: 895-900.
124. Resnicoff M, Sell C, Rubini M, et al. Rat glioblastoma cells expressing an antisense RNA to the insuline-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54(8): 2218-2222.
125. Andrews DW, Resnicoff M, Flanders AE, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insuline-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19(8): 2189-2200.
126. Liu TJ, La Fortune T, Honda T, et al. Inhibition of both adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007; 6: 1357-1367.
127. Wu ZM, Yuan XH, Jiang PC, Li ZQ, Wu T. Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J NeuroOncol 2006; 77(2): 117-123.
128. Park MJ, Kim MS, Park IC, et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinases-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphrylation. Cancer Res 2002; 62: 6318-6322.
129. Pu P, Kang C, Li J, Jiang H, Cheng J. The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo. J NeuroOncol 2006; 76: 1-11.
130. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Rainer Wirtz C. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumors. Cancer Treat Rev 2006; 32: 74-89.
131. Chu S, Yuan X, Li Z, Jiang P, Zhang J. c-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surg Neurol 2006; 65: 533-538.
132. Chu S, Zhu Z, Yuan X, Li Z, Jiang P. in vitro and in vivo Potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol 2006; 80(2): 143-149.
133. Chu S, Zang H, Ma Y, et al. c-Met antisense oligonucleotides as a novel therapeutic agent for glioma: in vitro and in vivo Studies of uptake, effects, and toxicity. J Surg Res 2007; 141(2): 284-288.
134. Khazenzon NM, Ljubimov AV, Lakhter AJ, et al. Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol Cancer Ther 2003; 2(10): 985-994.
135. Mohanam S, Chintala SK, Go Y, et al. in vitro Inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997; 14(11): 1351-1359.
136. Dias N, Stein CA. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2000; 54: 263-269.
137. Julien T, Frankel B, Longo S, et al. Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol 2000; 53(4): 360-369.
138. Guensberg P, Wacheck V, Lucas T, et al. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 2002; 48(4): 189-195.
139. Zalewski, A., Shi, Y.: US20006133242 (2000).
140. Bandman, O., Corley, N.C., Guegler, K.J.: US20016303765 (2001).
141. Schlingensiepen, G.F., Brysch, W., Schlingensiepen, K.H.: US20026455689 (2002).
142. Baker, B.F., Cowsert, L.M.: US20030105044 (2003).
143. McKay, R., Dean, N., Monia, B., Nero, P., Gaarde, W.A.: US20040029823A1 (2004).
144. Khare, R., Elliott, V.S., Marquis, S.P.: US20070124581 (2007).
145. Grandis, J.R.: US2008234181A1 (2008).
146. Rodriguez-Lafrasse, C., Hadchity, E.: WO2008106781A1 (2008).
147. Schlingensiepen, K.H., Schlingensiepen, R.: MX2007007184 (2008).
148. Adwan, H.: US2009017103A1 (2009).
149. Beri, R.: EP2025752 (2009).
150. Wedemann A, Johnson RS. Biology of HIF-1α. Cell Death Differ 2008; 15: 621-627.
151. Venza M, Caffo M, Caruso G, et al. C. IL-8 and prostaglandin E synthase expression in low and high grade human glioma. Molecular Mechanisms in Neuroscience. Milan, June 2008.
152. Caffo M, Caruso G, Raudino G, et al. Interleukin-8 and prostaglandin E synthase-1 expression in cerebral gliomas. 57° National Congress of Italian society of Neurosurgery; Milan, November 2008.